[{"id":"214315f7-683e-466c-9f58-c9d4a83789fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349569","created_at":"2021-01-18T05:30:46.129Z","updated_at":"2025-02-25T14:32:46.687Z","phase":"Phase 2","brief_title":"Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission","source_id_and_acronym":"NCT01349569","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • allogeneic Myeloma GM-CSF Vaccine"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2019-01-15"}]